医疗器械赛道的长期向好趋势不变，医疗器械ETF（562600）或可助您一键布局。该ETF所跟踪的中证 全指医疗器械指数精心选取 100 支覆盖医疗器械、医疗服务、医疗信息化等核心医疗领域的代表性上市 公司证券作为样本，能够有效捕捉细分赛道的结构性增长机会。场外用户亦则可选择华夏中证全指医疗 器械ETF发起式联接A（021250）和华夏中证全指医疗器械ETF发起式联接C（021251），进行便捷布局 （文章来源：每日经济新闻） 11月14日早盘，A股市场低开震荡。盘面上，医疗板块整体活跃，截至9点58分，医疗器械ETF （562600）涨0.22%，并连续12个交易日获得资金净流入。持仓股中，热景生物、利德曼涨超10%，华 兰股份、佰仁医疗、英诺特等股涨势靠前。 消息面上，11月13日晚，成分股利德曼发布《重大资产购买报告书（草案）》称，公司拟以支付现金的 方式向上海百家汇投资管理有限公司、南京百佳瑞企业管理咨询合伙企业（有限合伙）、海南先声百家 汇科技发展有限公司购买其所持有的先声祥瑞70%股份，交易作价17.33亿元。根据规定，本次交易标 的资产总额、资产净额、营业收入均超过上市公司的50%，构成重大资产重 ...

医疗器械赛道的长期投资逻辑清晰，医疗器械ETF（562600）或可助您一键布局。该ETF所跟踪的中证 全指医疗器械指数精心选取 100 支覆盖医疗器械、医疗服务、医疗信息化等核心医疗领域的代表性上市 公司证券作为样本，能够有效捕捉细分赛道的结构性增长机会。场外用户亦则可选择华夏中证全指医疗 器械ETF发起式联接A(021250)和华夏中证全指医疗器械ETF发起式联接C（021251)，进行便捷布局。 每日经济新闻 中泰证券指出，国内医疗器械行业正处于快速发展阶段，短期医保控费和国际形式在医疗器械领域可能 带来负面扰动，但长期依旧看好创新驱动下的进口替代以及全球化发展。当前时间点，预计多重负面影 响正在充分释放，器械板块已进入拐点区间，不同细分拐点节奏或有差异，值得持续重点关注。 11月12日，市场探底回升，沪指微跌。盘面上，医疗板块持续走强，医疗器械ETF（562600）收涨 0.76%，单日"吸金"超千万并连续12个交易日获得资金净流入，最新规模达到2.94亿元，创历史新高。 "AI＋医疗"按下"加速键"，近日五部门联合印发《关于促进和规范"人工智能+医疗卫生"应用发展的实 施意见》，系统规划了AI在医疗领 ...

Group 1 - A-share market opened lower but rose, with the medical device sector showing active performance, as the medical device ETF increased by 0.65% and has seen net inflows for 11 consecutive trading days, totaling over 90 million yuan [1] - The brain-computer interface field in China has made significant progress, with Shanghai Ladder Medical Technology's "implantable wireless brain-computer interface system" entering the special review process by the National Medical Products Administration, marking the first invasive brain-computer interface product to enter this "green channel" [1] - Guosen Securities noted that the rebound in equipment procurement in the first half of 2025 is gradually being recognized in Q3, with significant year-on-year improvements in revenue and net profit for the medical device sector in Q3 2025, driven by domestic economic recovery and equipment update tenders [1] Group 2 - The long-term positive trend in the medical device sector remains unchanged, with the medical device ETF (562600) providing a convenient way to invest in this area, tracking the CSI All-Share Medical Device Index which includes 100 representative listed companies in core medical fields [2] - Investors can also consider the 华夏中证全指医疗器械ETF发起式联接A (021250) and 华夏中证全指医疗器械ETF发起式联接C (021251) for easy allocation in the medical device sector [2]

消息面上，11月10日晚间，权重占比第一成分股迈瑞医疗发布公告，已于11月10日向香港联交所递交了 发行境外上市外资股（H股）并在香港联交所主板挂牌上市的申请，华泰国际和摩根大通为其联席保荐 人。 华源证券指出，中国医药产业已基本完成了新旧增长动能转换，医疗设备、供应链等已在全球范围内占 据较高的地位，在欧美发达市场以及新兴市场持续崭露头角，需求端和支付端也在持续推动新增量：一 方面银发经济长坡厚雪，另一方面医保收支仍在稳健增长，同时医保局积极推动商业保险的发展，构建 多层次支付体系；整体来看，三季度业绩开始企稳回升的医疗器械，尤其是医疗设备和家用器械板块尤 为值得关注。 11月11日早盘，A股市场高开走低。盘面上，医疗板块维持震荡态势。截至10:40，医疗器械ETF （562600）跌0.54%，并连续10个交易日获得资金净流入，持仓股济民健康、奕瑞科技、华兰股份等股 涨势靠前。 每日经济新闻 医疗器械赛道的长期向好趋势不变，医疗器械ETF（562600）或可助您一键布局。该ETF所跟踪的中证 全指医疗器械指数精心选取 100 支覆盖医疗器械、医疗服务、医疗信息化等核心医疗领域的代表性上市 公司证券作为样本 ...

Group 1 - The A-share market continues to rebound, with the medical sector showing a fluctuating consolidation trend, as evidenced by the medical device ETF declining by 0.33% but achieving a net inflow of funds for six consecutive trading days, reaching a record high of 246 million yuan [1] - Key stocks in the medical device sector, such as Hualan Biological Engineering and Furuide, are experiencing significant upward momentum [1] - Company executives from Kaili Biomedical have recently increased their holdings in the company, demonstrating strong confidence in its future development by committing to not reduce their holdings for six months [1] Group 2 - The medical device sector is expected to have structural investment opportunities, with fluctuations in certain stocks linked to third-quarter earnings disclosures [1] - Short-term strategies should focus on companies expected to improve their performance and valuation by 2026, as several leading firms in the medical device industry are projected to experience accelerated growth [1] - Long-term investment opportunities in the medical device sector are driven by innovation, international expansion, and mergers and acquisitions, with the sector's innovation and globalization capabilities gaining recognition and leading to a revaluation of its stocks [1] Group 3 - The long-term positive trend in the medical device sector remains unchanged, with the medical device ETF (562600) providing a convenient way to invest in this area [2] - The ETF tracks the CSI All Index Medical Device Index, which carefully selects 100 representative listed companies in core medical fields, effectively capturing structural growth opportunities in the sector [2] - Investors can also consider alternative options such as the Huaxia CSI All Index Medical Device ETF Initiated Link A (021250) and Link C (021251) for easy investment access [2]

Group 1 - The A-share market opened lower but the medical device sector showed active performance, with the medical device ETF (562600) rising nearly 1% and attracting a net inflow of 47 million over five consecutive trading days [1] - The National Medical Products Administration released a new version of the "Medical Device Production Quality Management Standards," effective from November 1, 2026, aimed at enhancing the quality management system of medical device companies in China [1] - According to Founder Securities, the medical device industry is nearing the end of its adjustment cycle, with clear trends of marginal improvement at both industry and company levels, highlighting opportunities for recovery from the bottom [1] Group 2 - The long-term investment logic in the medical device sector is clear, and the medical device ETF (562600) can facilitate easy investment in this area, tracking the CSI All Index for medical devices, which includes representative listed companies in core medical fields [2] - Investors can also consider alternative options such as the 华夏中证全指医疗器械ETF发起式联接A (021250) and 华夏中证全指医疗器械ETF发起式联接C (021251) for convenient investment [2]

Group 1 - The A-share market opened slightly lower on November 4, with the medical sector experiencing a minor pullback, as the medical device ETF (562600) fell nearly 1.20% by 10:30 AM, with a turnover rate exceeding 7% [1] - The Ministry of Finance released a draft notice on October 28, 2025, aimed at addressing the issue of abnormally low prices in government procurement, proposing a quantitative index to establish a review mechanism, which is expected to positively impact the medical device market [1] - In the third quarter of 2025, the overall market size of medical device bidding in China grew by 29.8% year-on-year, indicating a stable growth trend despite a slight decline in growth rate compared to the first and second quarters [1] Group 2 - The long-term positive trend in the medical device sector remains unchanged, with the medical device ETF (562600) providing an efficient way to invest in this area [2] - The ETF tracks the CSI All-Share Medical Device Index, which carefully selects 100 representative listed companies in core medical fields, effectively capturing structural growth opportunities in the sector [2] - Investors can also consider alternative options such as the Huaxia CSI All-Share Medical Device ETF Initiated Link A (021250) and Link C (021251) for convenient investment [2]

Core Viewpoint - The medical device sector is experiencing significant growth, driven by favorable policies and market dynamics, particularly highlighted by the recent changes in national procurement policies aimed at stabilizing pricing and promoting healthy industry development [1]. Group 1: Market Performance - On October 31, the Shanghai Composite Index opened lower, but the medical sector remained active, with the medical device ETF (562600) rising over 1.4% and a turnover rate of 5.2% [1]. - Notable stocks within the medical device sector include Cai Na Co. and Chunli Medical, both of which saw increases exceeding 10%, while companies like Tuo Jing Life and Zhen De Medical also performed well [1]. Group 2: Policy Impact - The National Healthcare Security Administration recently released the 11th batch of centralized procurement documents, which aims to prevent excessively low bidding by optimizing the selection of price control anchors, moving away from simply choosing the lowest bid [1]. - This policy change reflects the government's commitment to combating "involution" in the pharmaceutical sector, which is expected to extend to the medical device industry, fostering a return to healthy development and benefiting the domestic medical industry as a whole [1]. Group 3: Investment Opportunities - The medical device industry is poised for growth, and investors can leverage the medical device ETF (562600) to capture these opportunities, as it tracks the CSI All-Share Medical Device Index, which includes 100 representative companies with a high concentration of 89.3% in the medical device sector [1]. - For external investors, options such as the Huaxia CSI All-Share Medical Device ETF Initiated Link A (021250) and Link C (021251) are available for convenient investment [1].